Swiss Re’s Biogen BIIB Stock Holding History

Swiss Re’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-90	Closed	-$16.5K	–	245
2026 Q1	$16.5K	Hold	90	–	–	0.1%	155
2025 Q4	$15.8K	Buy	+90	New	+$14.7K	﹤0.01%	163

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Swiss Re's BIIB Position: Q2 2026 in Review

Swiss Re sold out of Biogen (BIIB) in Q2 2026, closing a stake of 90 shares — an estimated $16.5K sold.

Swiss Re first reported a position in BIIB in Q4 2025 and held it in 2 quarters. The position peaked at $16.5K in Q1 2026. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Swiss Re reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Swiss Re sold 90 Biogen shares in Q2 2026, an estimated $16.5K.
Swiss Re first reported a position in Biogen in Q4 2025 and held it in 2 quarters.
Swiss Re's Biogen position peaked at $16.5K in Q1 2026.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Swiss Re's 13F filing for Q2 2026, filed 11 Aug 2026.